about
Antibodies specifically targeting a locally misfolded region of tumor associated EGFRA Possible Role for Metallic Ions in the Carbohydrate Cluster Recognition Displayed by a Lewis Y Specific AntibodyStructural Basis for Fc RIIa Recognition of Human IgG and Formation of Inflammatory Signaling ComplexesComparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomesAntibody therapy of cancerInternalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody.Glycoprotein A33 deficiency: a new mouse model of impaired intestinal epithelial barrier function and inflammatory disease.Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies.L-Tyrosine Confers Residualizing Properties to a d-Amino Acid-Rich Residualizing Peptide for Radioiodination of Internalizing Antibodies.Quantitative intratumoural microdistribution and kinetics of (131)I-huA33 antibody in patients with colorectal carcinoma.Antibody inhibiting enzymatic activity of tumour-associated carbonic anhydrase isoform IX.Generalized Lymph Node Activation after Influenza Vaccination on 18F FDG-PET/CT Imaging, an Important Pitfall in PET Interpretation.Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.Hypoxia-controlled EphA3 marks a human endometrium-derived multipotent mesenchymal stromal cell that supports vascular growth.A First-Time-In-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial MinicellsTargeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumour vascular normalizationVascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer.Antibodies binding the ADAM10 substrate recognition domain inhibit Eph functionEngineering anti-Lewis-Y hu3S193 antibodies with improved therapeutic ratio for radioimmunotherapy of epithelial cancersPET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer.Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism.Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.Identification and characterization of EGF receptor in individual exosomes by fluorescence-activated vesicle sorting.In vivo imaging of cellular proliferation in renal cell carcinoma using 18F-fluorothymidine PETGlioma Specific Extracellular Missense Mutations in the First Cysteine Rich Region of Epidermal Growth Factor Receptor (EGFR) Initiate Ligand Independent Activation.Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor.The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.Control of glioblastoma tumorigenesis by feed-forward cytokine signaling.An activated form of ADAM10 is tumor selective and regulates cancer stem-like cells and tumor growth.Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemiaEstablished, emerging and future roles of PET/CT in the management of colorectal cancer.In Vitro and In Vivo Evaluation of 89Zr-DS-8273a as a Theranostic for Anti-Death Receptor 5 Therapy.Functional imaging of renal cell carcinoma.Therapeutic targeting of the epidermal growth factor receptor in human cancer.Monoclonal antibody dose determination and biodistribution into solid tumors.Current role of PET, CT, MR for invasive bladder cancer.FDG PET/CT in the liver: lesions mimicking malignancies.EphA3 biology and cancer.Structural biology of antibody recognition of carbohydrate epitopes and potential uses for targeted cancer immunotherapies.Standardization of administered activities in pediatric nuclear medicine: a report of the first nuclear medicine global initiative project, part 1-statement of the issue and a review of available resources.
P50
Q27654155-02EA32EB-D4FB-4C73-8FB6-64C40B5E95DCQ27658123-DD523C37-6AAC-4727-BE61-67FF1A2A32A8Q27671845-768BD0AA-96B9-4EFE-9F35-5AE634DE754BQ28258350-FC3D60A7-E32D-4164-9EC0-FF0AF44AC0D5Q28262538-EC6CD7F3-9E3C-42A0-9B4A-0B546943BA4EQ30480832-660E9FBF-0ECF-44A7-9FDA-62C966CC1BC8Q30660209-806C3529-B03A-4775-A5B1-4BB5B8494FBBQ31095363-752612DE-348C-4CD8-8363-55708F29C24AQ33795428-ECA49DCE-1232-405C-A2E1-54C82A2D536DQ33803210-5A9D02FA-15A7-4BBE-88D6-4139BA5719E3Q33818995-35C5F271-F86A-4957-8E21-316CCD78C4FBQ33830246-A03ED685-D620-4316-A0ED-625A46A07ED1Q34236834-80B37BD6-E275-4F23-82C1-83F90A14A377Q34566091-F8D8E1A8-839B-4170-B76A-C0E1DD6AD417Q35867171-CF6C1FFD-FA4B-48A8-A2D3-F26898E6524EQ35893456-9A539862-198D-4D2C-8E38-E9E09D6AF1E5Q36286704-17ECE497-EA86-461B-8FD1-E59955A6DCF8Q36648232-7973255B-C81D-4ED9-A0C8-0FFAFB2E3513Q36699195-13F902AD-93A6-4583-AD86-B159C05B3E8FQ36911658-34DE5465-183F-42CE-B539-9F7F148367D2Q36995979-7210B853-C119-4476-A885-8F96229C1FFFQ37002044-C2F9BB65-53C3-40FE-BA9D-AB8BA9204C0FQ37039717-8699476F-924C-4E6E-9D08-8B1209E98BE5Q37077354-7706F9B5-F861-40F9-B2F4-B6B4BF50D009Q37132712-A29E437F-4429-4641-8231-5BE06E20003CQ37138959-E463C52C-C944-4D43-BCDC-E45AD1D6F50EQ37165851-F343F9ED-2F4B-4B85-A447-0BD6AA828511Q37174174-F7F956B5-19DF-49B2-891C-627CB95EE497Q37197906-5BCE5F0F-77A6-4CC7-A23C-06B377666687Q37316845-F3C6FB52-D49E-4640-B62A-6E732FFB9DFBQ37382723-2B67DC38-F07B-4339-8BBE-DCD941361230Q37469866-33C6D93F-F731-4E9A-9736-9B9E3C6F578BQ37744505-B1C38BC2-BE6E-457D-941F-F569694B6A7DQ37999440-01E07AA9-0E20-4827-864C-E1DF28C6E2D9Q38029667-A1EFCE42-B86C-4058-9B78-E296340BD4CBQ38080034-D979EF97-E3B2-49B7-BA63-E5C6D0D909E2Q38162742-9D52165D-8982-443A-9B47-D58C1E2D626CQ38267753-934BA7B4-E056-43E7-9BDD-F907038DAE17Q38372538-D80D6A85-9F5A-4977-9F82-787C6B8F7BEBQ38376222-6C824626-47FE-43A6-8F18-D1D6BB4659E0
P50
description
researcher ORCID ID = 0000-0002-6656-295X
@en
wetenschapper
@nl
name
Andrew M Scott
@ast
Andrew M Scott
@en
Andrew M Scott
@es
Andrew M Scott
@nl
type
label
Andrew M Scott
@ast
Andrew M Scott
@en
Andrew M Scott
@es
Andrew M Scott
@nl
prefLabel
Andrew M Scott
@ast
Andrew M Scott
@en
Andrew M Scott
@es
Andrew M Scott
@nl
P106
P31
P496
0000-0002-6656-295X